A reappraisal of loop diuretic choice in heart failure patients

American Heart Journal
Jonathan BuggeyChristopher M O'Connor

Abstract

The health and economic burden of heart failure is significant and continues to grow each year. Loop diuretics are an integral part of symptom management in heart failure. Furosemide is used disproportionately compared with other loop diuretics, and there is currently no guidance for physicians regarding which agent to choose. However, there exist pharmacologic differences as well as other mechanistic differences that appear to favor torsemide use over furosemide. Compared with furosemide, torsemide improves surrogate markers of heart failure severity such as left ventricular function, plasma brain natriuretic peptide levels, and New York Heart Association functional class and may also reduce hospitalizations, readmissions, and mortality. Data suggest that these benefits could be mediated through torsemide's ability to positively affect the renin-angiotensin-aldosterone system. Specifically, torsemide has been shown to inhibit aldosterone secretion, synthesis, and receptor binding in vitro, as well as decrease transcardiac extraction of aldosterone, myocardial collagen production, and cardiac fibrosis in patients with heart failure. We identified pertinent literature using keyword MEDLINE searches and cross-referencing prior bi...Continue Reading

References

Nov 26, 1991·European Journal of Pharmacology·T UchidaM Watanabe
Jan 1, 1987·British Heart Journal·J BaylissP Poole-Wilson
Mar 1, 1985·Annals of Internal Medicine·M R VaskoD C Brater
Aug 1, 1984·Kidney International·D C BraterS Anderson
Jan 1, 1984·Journal of Toxicology. Clinical Toxicology·N N Khanna, S M Somani
Aug 11, 1998·Life Sciences·T L GoodfriendV Bähr
Sep 2, 1998·Journal of Clinical Pharmacology·B E BleskeJ M Nicklas
Sep 15, 2000·Journal of the American College of Cardiology·T TsutamotoM Kinoshita
May 23, 2001·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·P MuñizJ Díez
Jul 1, 1995·American Journal of Therapeutics·William G. Kramer
Aug 9, 2002·European Journal of Heart Failure·Juan CosínUNKNOWN TORIC investigators
May 9, 2003·Circulation Journal : Official Journal of the Japanese Circulation Society·Masaki YamatoTakaharu Hayashi
Jun 7, 2003·Circulation Research·Wenning QinEllen G McMahon
Sep 19, 2003·Lancet·Marc A PfefferUNKNOWN CHARM Investigators and Committees
Jun 3, 2004·Journal of the American College of Cardiology·Begoña LópezJavier Díez
Sep 15, 2004·Journal of the American College of Cardiology·John M McCurleyMark C Haigney
Dec 8, 2004·Journal of the American College of Cardiology·Takayoshi TsutamotoMinoru Horie
Aug 28, 2007·European Journal of Heart Failure·Vic HasselbladKirkwood F Adams
Aug 28, 2007·Journal of the American College of Cardiology·Begoña LópezJavier Díez
Nov 16, 2007·Biochemical Pharmacology·Punniyakoti T VeeraveeduYoshifusa Aizawa
Mar 25, 2008·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Hironori HayashiHiroaki Matsubara
Aug 2, 2008·Journal of the American College of Cardiology·Jing FangNora L Keenan
Oct 22, 2008·Cardiology·W Franklin PeacockUNKNOWN ADHERE Scientific Advisory Committee and Investigators
Apr 14, 2010·Circulation·Begoña LópezJavier Díez
Sep 30, 2010·The Pharmacogenomics Journal·S V Vormfelde, J Brockmöller
Nov 16, 2010·The New England Journal of Medicine·Faiez ZannadUNKNOWN EMPHASIS-HF Study Group
Jun 9, 2012·Journal of the American College of Cardiology·G Michael Felker, Robert J Mentz
Sep 28, 2012·Future Cardiology·James J DiNicolantonio

❮ Previous
Next ❯

Citations

Dec 26, 2015·The American Journal of Cardiology·Robert J MentzChristopher M O'Connor
Jul 3, 2016·Heart Failure Clinics·Valentina CarubelliRobert J Mentz
Apr 4, 2018·Heart Failure Reviews·Joyce N NjorogeMihai Gheorghiade
Oct 31, 2017·European Journal of Heart Failure·Stephen J Greene, Robert J Mentz
Oct 5, 2017·Journal of Veterinary Internal Medicine·V ChetboulUNKNOWN TEST study investigators
Feb 23, 2019·BMJ : British Medical Journal·Steven D AnismanNancy E Morden
Apr 6, 2019·Journal of Cardiovascular Medicine·Jeremy A MilesDamianos G Kokkinidis
Feb 24, 2017·American Journal of Physiology. Renal Physiology·Magali AraujoChristopher S Wilcox
Jan 3, 2018·Expert Review of Cardiovascular Therapy·Valentina CarubelliLars H Lund
Dec 12, 2019·Clinical Cardiology·Magali P A Disdier MoulderNarith N Ou
Aug 23, 2019·Journal of Evaluation in Clinical Practice·Nourin Ali SherifNguyen Tien Huy
Apr 22, 2017·Frontiers in Pharmacology·Lu FangAnthony M Dart
Mar 1, 2017·Current Heart Failure Reports·E Ashley Hardin, Justin L Grodin
Nov 16, 2017·The New England Journal of Medicine·David H Ellison, G Michael Felker
Feb 10, 2021·Expert Opinion on Pharmacotherapy·Bharat NarasimhanWilbert S Aronow
Mar 15, 2021·JACC. Heart Failure·Stephen J GreeneUNKNOWN TRANSFORM-HF Investigators
Dec 23, 2021·Expert Review of Cardiovascular Therapy·Anthony E PetersStephen J Greene

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Biomarkers for Cardiovascular Risk Assessment

Sensitive and accurate biomarkers used in cardiovascular risk prediction can potentially be used to manage the risk of cardiovascular disease. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here.